|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Pharmacia and Upjohn |
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002236 |
Purpose
The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.
| Condition | Intervention |
|
HIV Infections |
Drug: Indinavir sulfate Drug: Delavirdine mesylate Drug: Zidovudine |
| MedlinePlus related topics: | AIDS |
| Drug Information available for: | Zidovudine Indinavir Indinavir Sulfate Delavirdine mesylate Delavirdine |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label, Pharmacokinetics Study |
| Official Title: | An Open-Label, Parallel Group, Pilot Study of Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of BID and TID Regimens of Delavirdine Mesylate, Zidovudine, and Indinavir Sulfate in HIV-1 Infected Individuals |
| Estimated Enrollment: | 32 |
Patients are divided into 2 treatment groups; the groups are balanced with respect to viral load. Group A receives ZDV, DLV, and IDV 3 times daily. Group B receives ZDV, DLV, and IDV 2 times daily. Patients are evaluated for changes from baseline in viral load and CD4 cell count.
Eligibility
| Ages Eligible for Study: | 14 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
You may be eligible for this study if you:
Exclusion Criteria
You will not be eligible for this study if you:
Contacts and Locations| United States, California | |||||
| AIDS Healthcare Foundation | |||||
| Los Angeles, California, United States, 90027 | |||||
| UCSF AIDS Research Institute | |||||
| San Francisco, California, United States, 94105 | |||||
| United States, New York | |||||
| Saint Luke's - Roosevelt Hosp Ctr | |||||
| New York, New York, United States, 10019 | |||||
| United States, Pennsylvania | |||||
| Anderson Clinical Research | |||||
| Pittsburgh, Pennsylvania, United States, 15213 | |||||
| United States, Tennessee | |||||
| Univ of Tennessee / Div of Infect Dis / Dept of Med | |||||
| Memphis, Tennessee, United States, 38165 | |||||
| United States, Virginia | |||||
| Infectious Disease Physicians Inc | |||||
| Annandale, Virginia, United States, 22203 | |||||
| Pharmacia and Upjohn |
More Information
| Study ID Numbers: | 228G, M/3331/0072 |
| First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002236 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|